J7677 HCPCS code: Revefenacin inhalation solution, fda-approved final product, non-compounded, administered through dme, 1 microgram
J7677 is the HCPCS Level II code for revefenacin inhalation solution, fda-approved final product, non-compounded, administered through dme, 1 microgram. In 2024 Medicare paid an average of $0.15 per service for J7677 across 826 services. Its Medicare coverage code is C (Carrier judgment): Coverage is decided by the Medicare contractor (MAC) case by case. The NCCI unit limit is 175 per day on outpatient hospital claims. Medicare volume rose 123% from 2022 to 2024 (370 to 826 services). In 2024, 4,532 suppliers billed Medicare for J7677 (purchases), serving 29,205 beneficiaries; Texas, California, Florida accounted for 20% of services.
Code details
| Field | Value |
|---|---|
| Section | J codes — Drugs administered other than oral method |
| Coverage code | C — Carrier judgment |
| Pricing indicator | 51 — Drug or biological (priced per ASP/average sales price rules) |
| BETOS category | D1G — Drugs administered through DME |
| Added | 2019-07-01 |
| Last action effective | 2019-07-01 |
Who bills J7677 (2024)
| Measure | Value |
|---|---|
| Suppliers billing rentals | — |
| Suppliers billing purchases | 4,532 |
| Referring clinicians | 10,496 |
| Medicare beneficiaries | 29,205 |
| States with claims | 52 |
| Share of services in top 3 states (Texas, California, Florida) | 20% |
| Year | Suppliers | Beneficiaries |
|---|---|---|
| 2022 | 4,483 | 27,005 |
| 2023 | 4,719 | 28,751 |
| 2024 | 4,532 | 29,205 |
Counts only. Supplier and clinician names, contact lists and state-by-state detail are in Caduvo.
Medicare utilization for J7677, 2022–2024
| Year | Services | Beneficiaries | Avg. allowed | Avg. paid |
|---|---|---|---|---|
| 2022 | 370 | 18 | $0.18 | $0.14 |
| 2023 | 196 | 20 | $0.18 | $0.14 |
| 2024 | 826 | 44 | $0.18 | $0.15 |
States with the most J7677 services (2024)
| State | Services | Avg. paid |
|---|---|---|
| Illinois | 43 | $0.14 |
NCCI unit limits (MUE)
| Claim type | Max units per day | Rationale |
|---|---|---|
| outpatient hospital claims | 175 | Prescribing Information |
| practitioner claims | 175 | Prescribing Information |
Medicare policy articles for this code
- A52466: Nebulizers - Policy Article (CGS Administrators, LLC (DME MAC) Noridian Healthcare Solutions, LLC (DME MAC)) — mentions this code in its coding guidance
Covered diagnoses (215 ICD-10-CM codes)
The diagnoses most often listed as covered in the policy articles above:
| ICD-10-CM | Diagnosis | Articles listing it |
|---|---|---|
| A15.0 | Tuberculosis of lung | 1 |
| A22.1 | Pulmonary anthrax | 1 |
| A37.01 | Whooping cough due to Bordetella pertussis with pneumonia | 1 |
| A37.11 | Whooping cough due to Bordetella parapertussis with pneumonia | 1 |
| A37.81 | Whooping cough due to other Bordetella species with pneumonia | 1 |
| A37.91 | Whooping cough, unspecified species with pneumonia | 1 |
| A48.1 | Legionnaires' disease | 1 |
| B20 | Human immunodeficiency virus [HIV] disease | 1 |
| B25.0 | Cytomegaloviral pneumonitis | 1 |
| B44.0 | Invasive pulmonary aspergillosis | 1 |
Showing 10 of 215. The full list, non-covered diagnoses and CSV export are in Caduvo.
What changed for J7677
- 2019-07-01: J7677 added to HCPCS Level II
- Next scheduled CMS quarterly update (HCPCS and DMEPOS fee schedule): 2027-01-01
Frequently asked questions
What is HCPCS code J7677?
J7677 is the HCPCS Level II code for revefenacin inhalation solution, fda-approved final product, non-compounded, administered through dme, 1 microgram. Short descriptor: "Revefenacin inh non-com 1mcg".
How much does Medicare pay for J7677?
In 2024, the average Medicare payment was $0.15 per service (average allowed $0.18).
Does Medicare cover J7677?
Coverage code C — Carrier judgment. Coverage is decided by the Medicare contractor (MAC) case by case.
Which diagnoses support coverage for J7677?
Medicare policy articles that cite J7677 list 215 covered ICD-10-CM diagnosis codes across 1 article. The most cited include A15.0 (Tuberculosis of lung), A22.1 (Pulmonary anthrax), A37.01 (Whooping cough due to Bordetella pertussis with pneumonia). A listed diagnosis is necessary but not sufficient; the policy's other criteria still apply.
How many units of J7677 can be billed per day?
175 on outpatient hospital claims; 175 on practitioner claims (NCCI medically unlikely edits).
Related J76 codes
- J7601 — Ensifentrine, inhalation suspension, fda approved final product, non-compounded, administered through dme, unit dose form, 3 mg
- J7604 — Acetylcysteine, inhalation solution, compounded product, administered through dme, unit dose form, per gram
- J7605 — Arformoterol, inhalation solution, fda approved final product, non-compounded, administered through dme, unit dose form, 15 micrograms
- J7606 — Formoterol fumarate, inhalation solution, fda approved final product, non-compounded, administered through dme, unit dose form, 20 micrograms
- J7607 — Levalbuterol, inhalation solution, compounded product, administered through dme, concentrated form, 0.5 mg
- J7608 — Acetylcysteine, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per gram
- J7609 — Albuterol, inhalation solution, compounded product, administered through dme, unit dose, 1 mg
- J7610 — Albuterol, inhalation solution, compounded product, administered through dme, concentrated form, 1 mg
- J7611 — Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 1 mg
- J7612 — Levalbuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 0.5 mg
- J7613 — Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg
- J7614 — Levalbuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 0.5 mg
Building a device that would bill under a code like this? Caduvo matches a device description to HCPCS/CPT codes, Medicare coverage and payment, and the FDA pathway in one report.
Next steps
- Run a reimbursement report for a device billed under J7677
- Watch J7677 for fee, coverage and descriptor changes
- Build a full Medicare revenue model for J7677
Compiled by Caduvo from public CMS (Medicare) records, HCPCS release October 2026. Fees are Medicare allowables, not commercial rates. Not reviewed or endorsed by CMS. Not billing or legal advice. Report an error. Data and corrections policy.